Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.
External link for Alkeus Pharmaceuticals, Inc.
.
Cambridge, MA, US
Alkeus Pharmaceuticals, Inc. reposted this
“One of the first things patients lose in macular degeneration is low light vision, which can have a dramatic impact on daily living. The positive effect demonstrated on low luminance visual acuity (LLVA) is significant. Based on these results, this therapy would definitely have a place in the overall strategy of treating AMD and slowing the decline observed in our patients. The favorable safety profile could warrant treatment as early as possible.”
We recently had the pleasure of speaking with Renee and Mike, parents of Miles, an amazingly talented musician living with Stargardt disease. Their inspiring story is now live on the YourNorthStarg.com website. We are honored to have the opportunity to share their #Stargardt experience with you. Julia Carpenter-Conlin MSW, Paula Pearson https://lnkd.in/eaUgDBKG #YourNorthStarg #Stargardt #AlkeusPharma #patientvoices #blindnessawarenessmonth
We're #hiring a new Director, Clinical Data Management in Cambridge, Massachusetts. Apply today or share this post with your network.
Alkeus Pharmaceuticals, Inc. reposted this
The top 10 takeaways from AAO 2024: This year’s conference in Chicago showcased a diverse array of practice-changing data across multiple ophthalmic specialties, including advances in cataract surgery, glaucoma management, and retinal disease treatments. Read More: https://lnkd.in/eh-gckP5
Topline results from the clinical study of our investigational oral therapy for the potential treatment of geographic atrophy were presented at the AAO 2024 annual meeting in Chicago. Read today's press release here: https://lnkd.in/gWShQPBd #alkeuspharma #geographicatrophy #AAO2024 #biotechnews #Stargardt
We are having an amazing time at #AAO2024.
We had a great time at #AAO2024 today in Chicago. If you are attending the conference, stop by booth #1528 to hear about our clinical advancements. Birva Kadakia Shah O.D., Debbie Elizabeth Etchison, Aria Cohen, and Julia Carpenter-Conlin MSW. #alkeuspharma #YourNorthStarg #stargardt
We had a great time at #AAO2024 today in Chicago. If you are attending the conference, stop by booth #1528 to hear about our clinical advancements. Birva Kadakia Shah O.D., Debbie Elizabeth Etchison, Aria Cohen, and Julia Carpenter-Conlin MSW. #alkeuspharma #YourNorthStarg #stargardt
We are excited to be at #AAO2024. If you are in Chicago, visit us at booth 1528 to learn more about our work as we strive to make a difference in the lives of those living with retinal diseases. Paula Pearson, Birva Shah, Julia Carpenter-Conlin MSW #AlkeusPharma #Stargardt #geographicatrophy
Alkeus President and CEO Michel Dahan was interviewed today by EyewireTV during Eyecelerator at AAO. It was an honor, and we are looking forward to the scientific exchange at AAO. #AlkeusPharma #AAO2024
Data from our clinical studies will be presented at the American Academy of Ophthalmology (AAO) 2024 annual meeting in Chicago. Read our press release: https://lnkd.in/eqcCrdGA #AAO2024 #AlkeusPharma #geographicatrophy #stargardt